Compare IQIYI Inc - ADR (IQ) vs TG Therapeutics Inc (TGTX) Price & Performance

iQIYI (IQ) trades at $1.01, down 0.49% with bearish technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million for 2025. Analyst consensus is mixed with 50% buy ratings, while technical indicators show bearish momentum with neutral oscillators. Recent developments include the successful launch of AI-generated content series 'The Ferry Man' generating over RMB 8 million in revenue-sharing.

The outlook remains challenging with declining revenue trends and negative profitability, though the company's pivot to AI-driven content production offers potential cost savings. Key risks include streaming business contraction and Chinese regulatory environment. Wall Street maintains cautious optimism with 11 buy ratings but investors should monitor Q3 earnings for turnaround evidence.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.